|Pack Size||Qty||Price Per Pill or Unit||Price||Offer|
|30 Tablet/s||US$ 0.39||US$ 11.68||
|60 Tablet/s||US$ 0.39||US$ 23.36||
|90 Tablet/s||US$ 0.39||US$ 35.05||
|US Brand Name||Tricor|
Lipicard 160 mg is used as a monotherapy to reduce elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides and increase high-density lipoprotein in patients with hyperlipidemia or mixed dyslipidemia. It is also effective in reducing triglycerides in patients with severe hypertriglyceridemia. Each film-coated tablet contains 160 mg of Fenofibrate as the active constituent. The medicine appears to produce variable elevation of HDL cholesterol, a reduction in the content of the low-density lipoprotein cholesterol, and a significant reduction in the triglyceride content of very-low-density protein. After oral administration with food, Fenofibrate is rapidly hydrolyzed to Fenofibric acid, an active metabolite.
The recommended dose for adults is one tablet containing 160 mg Fenofibrate once daily. In elderly patients without renal impairment, the usual adult dose is recommended. Dose reduction is required in patients with kidney disease. In patients with severe chronic kidney disease, Lipicard 160 is not recommended. This Fenofibrate formulation is not recommended for use in patients with hepatic insufficiency. The safety and effectiveness of Lipicard tablets in children and adolescents younger than 18 years of age have not established. Therefore, the use of the cholesterol-lowering drug is not recommended in patients under 18 years of age.
Lipicard 160 mg should not be used in patients with severe renal impairment, including those undergoing dialysis. It can also be harmful to patients with active liver disease, unexplained persistent liver abnormalities, pre-existing bladder disease, nursing mothers, and patients with known hypersensitivity to Fenofibrate.
Caution should be exercised when Lipicard is used in combination with coumarin anticoagulants. A fenofibrate formulation The
Limited evidence in children and adolescents at Fenofibrate dose; therefore, it should be used with caution in such population.
Women of childbearing age must exercise strict birth control procedures. If pregnancy occurs despite following birth control measures, discontinue Fenofibrate. Women who are planning pregnancy should discontinue this cholesterol-lowering drug several months before conception.
This Fenofibrate formulation may increase cholesterol excretion into the bile and may cause cholelithiasis (gallstones). If a gallstone is suspected, treatment should be discontinued.
Mild white blood cell decreases have been observed in patients during the initial days of the treatment. Abnormal liver function has been observed during the treatment. However, the abnormalities disappear when therapy with Lipicard 160 is discontinued.
Treatment with cholesterol-lowering drugs is often associated with myositis in patients with impaired renal impairment.
Possible side effects of Lipicard 160 mg includes loss of appetite, fever, chills, sore throat, stomach pain just after eating a meal, mouth sores, chest pain, wheezing, sudden cough, unusual bruising, jaundice, coughing up blood, rapid breathing, weakness, swelling, warmth or redness in an arm or leg. Get immediate medical help if you develop any of these symptoms. The most common side effects of Fenofibrate are sneezing, runny nose and abnormal laboratory tests. You must inform your doctor if you have any side effects that bother you or do not go away.